The post Polymarket Sues Massachusetts Amid Prediction Market Crackdown appeared on BitcoinEthereumNews.com. As the prediction market crackdown intensifies in theThe post Polymarket Sues Massachusetts Amid Prediction Market Crackdown appeared on BitcoinEthereumNews.com. As the prediction market crackdown intensifies in the

Polymarket Sues Massachusetts Amid Prediction Market Crackdown

As the prediction market crackdown intensifies in the US, Polymarket has launched a lawsuit against Massachusetts. The move intends to block state officials from restricting the platform’s operations, arguing that the industry falls under federal oversight.

Polymarket filed a federal lawsuit against Massachusetts Attorney General Andrea Campbell and state gaming regulators earlier today. On February 10, the company claimed that the state-level action is limiting its operations, restricting users’ access to the platform.

Notably, the move comes on the heels of a recent setback for the prediction market platform Kalshi. Last Friday, Kalshi requested to pause a ban on its sports prediction markets. In November 2025, Kalshi was hit by a class action lawsuit, which alleged that the team was operating an unlicensed sports betting platform. Although Kalshi argued that prediction markets are regulated by the CFTC, the judge objected to the statement.

It is worth noting that these platforms are facing increased scrutiny in the country. Last month, Polymarket, Kalshi, and Crypto.com received a cease-and-desist letter from the Tennessee Sports Wagering Council. The move was intended to stop these platforms from offering sports betting contracts.

In the latest development, Polymarket also put forward a similar argument. According to Polymarket, prediction market regulation comes under the jurisdiction of the CFTC, not the state. Polymarket CLO Neal Kumar stated,

Previously, as CoinGape reported, crypto exchange Coinbase also filed a similar lawsuit against three US States, including Michigan, Illinois, and Connecticut. Coinbase challenged the US States’ prediction market oversight, which the exchange believes falls outside its control. The exchange also takes a similar approach to Polymarket and Kalshi, arguing that prediction markets should be overseen by the CFTC.

Polymarket Flags Threat to National Market Stability

Significantly, the lawsuit argues that the state-level regulation causes “imminent and irreparable harm.” The platform claims that the state is currently trying enforce its gambling laws on prediction platforms.

Polymarket also argued that penalties or restrictions could interfere with its legally approved operations, split the national market, reduce liquidity, strain banking and business partnerships, and weaken user confidence in the platform. The firm added,

According to Polymarket’s claims, CFTC is responsible for overseeing derivatives and futures markets, which include prediction markets as well. Further strengthening this statement, the lawsuit cited CFTC Chairman Michael Selig’s words. On January 29, 2026, Selig stated that his agency would review how it deals with cases that test its authority. This ongoing review is expected to shape the regulation of prediction markets in the US. 

Source: https://coingape.com/polymarket-sues-massachusetts-amid-prediction-market-crackdown/

Market Opportunity
Movement Logo
Movement Price(MOVE)
$0.02129
$0.02129$0.02129
-3.88%
USD
Movement (MOVE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26